SOURCE: Hansen Medical, Inc.

Hansen Medical, Inc.

July 28, 2011 17:30 ET

Hansen Medical Announces 2011 Second Quarter and Six-Month Results Conference Call

MOUNTAIN VIEW, CA--(Marketwire - Jul 28, 2011) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced today that it will release its financial and operating results for the second quarter and six months ended June 30, 2011 after market close on Wednesday, August 3, 2011.

Bruce Barclay, President and Chief Executive Officer, will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on August 3, 2011 to discuss the company's results. The call may be accessed by dialing 888-846-5003 (480-629-9713 for international callers) and via the Internet in the Investor Relations section of Hansen Medical's website at www.hansenmedical.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. Following the call, a webcast replay will be available on Hansen Medical's website, and an audio replay will also be available by calling 877-870-5176 (858-384-5517 for international callers) and entering the access code 4459833. The audio replay will be available through August 10, 2011.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company's Sensei® system and its Sensei X Robotic Catheter System were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Artisan and Sensei X system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Artisan and the Sensei X system are cleared for use during EP procedures, such as guiding catheters in the treatment of AF, and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. The company's Magellan Robotic System, which is intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, has undergone conformity assessment and CE marking and is commercially available in the European Union. The NorthStar Catheter and related accessories designed for use with the Magellan™ Robotic System are not yet CE marked. In the U.S., the Magellan Robotic System, the NorthStar Catheter and accessories are the subject of a current filing with the FDA and are not commercially available. Additional information can be found at www.hansenmedical.com.

Contact Information

  • Investor Contacts:
    Peter Mariani
    Chief Financial Officer
    Hansen Medical
    650.404.5800

    Matt Clawson
    Allen & Caron Inc
    949.474.4300
    Email Contact